🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseHas anyone dealt with mash biomarker panel? Page 5

Has anyone dealt with mash biomarker panel?

Dr.ObesityMed Mon, Jul 22, 2024 at 9:09 PM 27 replies 2,236 viewsPage 5 of 6
mike_nyc
VIP Member
5,678
21,345
Nov 2023
New York
Online
Aug 4, 2024 at 4:12 AM#21
Dr.AddMedPHL said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. Pushing back on the consensus forming here. Consistency is not the same as correctness, and a board that agrees with itself quickly is usually agreeing with the first person who sounded certain.

13 11maya_sedona, stefan_berlin, Dr.EM_Chicago and 10 others
Reply Quote Save Share Report
JessicaM_2024
Member
823
3,456
Mar 2024
Portland, OR
Aug 7, 2024 at 3:16 AM#22
Dr.AddMedPHL said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

True, and it depends on a baseline nobody has stated. Without knowing where someone started, the same number can be an excellent result or a disappointing one.

14 12NicoleRaleigh, james_edin, FranDenver and 11 others
Reply Quote Save Share Report
JenMemphis
Member
267
1,234
Jan 2025
Memphis, TN
Aug 10, 2024 at 2:19 AM#23
Dr.AddMedPHL said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

That reframing is the part I needed.

15 13NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 12 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.SportsMedIN
Senior Member
1,456
6,789
Feb 2024
Indianapolis, IN
Aug 13, 2024 at 1:20 AM#24

Clinical perspective, offered as context rather than as advice. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

Worth separating that from the baseline and follow-up panel, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Correct me if the detail matters more than I have assumed.

16 14Dr.SurgeonPGH, rachel_ABQ, traveltech_sara and 13 others
Reply Quote Save Share Report
oliver_london
Member
312
1,345
Aug 2024
London, UK
Aug 16, 2024 at 12:19 AM#25
Dr.SportsMedIN said:
It helps to ask what evidence would change your mind before you look at any.

Same experience, arrived at from the opposite direction.

17 15wendy_avl, jason_paloalto, Dr.LeslieOBGYN and 14 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register